AbbVie Q2 GAAP EPS climbs 290.4% to $2.03; net revenues rise 10.2% to $16.99 billion vs Q2 FY25 - ABBV News | RalliesAbbVie Q2 GAAP EPS climbs 290.4% to $2.03; net revenues rise 10.2% to $16.99 billion vs Q2 FY25
A
ABBV• Second-quarter results
- AbbVie posted second-quarter GAAP EPS of $2.03, up 290.4% from a year earlier; non-GAAP adjusted EPS rose 22.9% to $3.65.
- Net revenues increased 10.2% from a year earlier to $16.99 billion, led by immunology revenue up 15.1% to $8.79 billion.
- Skyrizi net revenues climbed 24.4% to $5.51 billion; Rinvoq net revenues rose 24.5% to $2.53 billion.
- Neuroscience net revenues grew 20.3% to $3.23 billion; oncology net revenues slipped 1.5% to $1.65 billion.
2026 guidance
- Guidance for 2026 non-GAAP adjusted EPS narrowed to $13.87-$14.07, including a $0.14 per-share dilutive impact from the planned Apogee acquisition.
